Publications (7)12.67 Total impact
-
Article: Differential Pathological Response to Preoperative Chemotherapy across Breast Cancer Intrinsic Subtypes.
[show abstract] [hide abstract]
ABSTRACT: Background: Breast cancer is a heterogeneous disease with a diversity of clinical behaviors. The purpose of this study was to evaluate the utility of breast cancer intrinsic subtypes in the prediction of pathological complete response (pCR) in a cohort of breast cancer patients receiving preoperative chemotherapy. Methods: Patients with stage II/III breast cancer received 4 cycles of XT (capecitabine and docetaxel) followed by 4 cycles of FEC (fluorouracil, epirubicin, and cyclophosphamide) as preoperative chemotherapy. Tumors were classified as luminal A, luminal B, luminal/HER2, HER2, basal-like, or non-basal-like triple negative by immunohistochemical analysis in core needle biopsy samples at baseline. Results: The overall pCR rate was 11.9% (12/101). Multivariate analysis showed that intrinsic subtype was an independent factor to predict pCR. With luminal A patients as the reference group, luminal B (OR = 16.39; 95% CI 1.44-185.88; p = 0.024), HER2 (OR = 14.73; 95% CI 1.19-180.84; p = 0.035), and basal-like (OR = 13.27; 95% CI 1.27-138.79; p = 0.031) patients had a significantly higher likelihood of pCR. Conclusion: The present data indicate that intrinsic subtypes may be useful predictive biomarkers of pCR in breast cancer patients treated with preoperative chemotherapy.Chemotherapy 11/2012; 58(5):364-370. · 1.82 Impact Factor -
Article: [HOXB9 as a novel prognostic factor in breast cancer].
Nippon rinsho. Japanese journal of clinical medicine 09/2012; 70 Suppl 7:166-9. -
Article: Correlation Between Clinical Nodal Status and Sentinel Lymph Node Biopsy False Negative Rate After Neoadjuvant Chemotherapy.
[show abstract] [hide abstract]
ABSTRACT: BACKGROUND: Neoadjuvant chemotherapy (NAC) is the standard treatment for locally advanced breast cancer. It is now being used to treat operable breast cancer to facilitate breast-conserving surgery, but the accuracy of sentinel lymph node biopsy (SLNB) in breast cancer patients receiving NAC remains open to considerable debate. METHODS: We enrolled 96 patients with stage II-III breast cancer who received NAC from January 2001 to July 2010. All patients underwent breast surgery and SLNB, followed immediately by complete axillary lymph node dissection (ALND). Sentinel lymph nodes were detected with blue dye and radiocolloid injected intradermally just above the tumor and then evaluated with hematoxylin and eosin and immunohistochemical staining. RESULTS: The overall identification rate for SLNB was 87.5 % (84/96); the false negative rate (FNR) was 24.5 % (12/49); and the accuracy rate was 85.7 % (72/84). The FNR was significantly lower in clinically node-negative patients than in node-positive patients before NAC (5.5 % vs. 35.5 %; p = 0.001). Accuracy was also significantly higher in clinically node-negative patients than in node-positive patients before NAC (97.2 % vs. 77.1 %; p = 0.009). The FNR was 27.3 % among 46 clinically node-positive patients before NAC who were clinically node-negative after NAC. Among 12 patients with a complete tumor response (CR), the FNR was 0 %, compared with 26.1 % for 83 patients with a partial response and stable disease (p = 0.404). CONCLUSIONS: Although associated with a high FNR after NAC, SLNB would have successfully replaced ALND in clinically node-negative patients before NAC and in patients with a CR after NAC.World Journal of Surgery 07/2012; · 2.36 Impact Factor -
Article: HOXB9 expression promoting tumor cell proliferation and angiogenesis is associated with clinical outcomes in breast cancer patients.
[show abstract] [hide abstract]
ABSTRACT: Studies have suggested that HOXB9 expression in breast cancer cells promotes cellular invasiveness, metastatic ability, and tumor neovascularization in the surrounding tissue in in vitro and in vivo assays. These findings imply that HOXB9 overexpression may alter tumor-specific cell fates and the tumor stromal microenvironment, contributing to breast cancer progression. The objective of this study was to analyze whether these results could be applied to clinical practice. A total of 141 consecutive, invasive ductal carcinoma patients who underwent surgical treatment were examined. Immunohistochemical staining was performed to evaluate the expression of HOXB9, Ki-67, CD31, and CD34, and the association of tumor proliferation and angiogenesis with HOXB9 expression was analyzed. Of the 141 tumor specimens immunostained for HOXB9, 69 (48.9%) stained positive. Larger primary tumor size, hormone receptor negativity, HER2 positivity, higher nuclear grade, and number of pathologic nodal metastases were significant variables associated with HOXB9 expression. Notably, 12 (92.3%) of 13 triple-negative breast cancer cases showed HOXB9 expression. Disease-free survival and overall survival were significantly different between the HOXB9-positive and HOXB9-negative groups (hazard ratio 20.714, P = 0.001; and hazard ratio 9.206, P = 0.003, respectively). Multivariate analysis indicated that HOXB9 expression was the only independent prognostic factor for disease-free survival (hazard ratio 15.532, P = 0.009). HOXB9-positive tumors showed a significant increase in the number of vasculature and the Ki-67 ratio compared with HOXB9-negative tumors. HOXB9 expression, which promotes tumor proliferation and angiogenesis, is a significant prognostic factor in breast cancer.Annals of Surgical Oncology 03/2012; 19(6):1831-40. · 4.17 Impact Factor -
Article: Primary systemic chemotherapy of breast cancer: indication and predictive factors.
[show abstract] [hide abstract]
ABSTRACT: Primary systemic chemotherapy has become a standard of care for operable breast cancer patients who are candidates for adjuvant chemotherapy. Induction of pathological complete response (pCR) is one of the main goals of primary systemic chemotherapy because patients with pCR have shown a better prognosis. The definition of pCR has varied across clinical trials. It would be ideal for all researchers to use the same terminology in describing pathologic response. Identification of accurate predictive factors of pCR to primary systemic chemotherapy is urgent, because patients with a low chance of pCR and clinical response should be spared unnecessary toxicity. Early response to primary systemic chemotherapy might be correlated with a high probability of a pCR. Therefore, evaluation of early response is useful to avoid unnecessary toxicity without potential benefit from chemotherapy.Breast Cancer 10/2010; 18(2):74-9. · 1.36 Impact Factor -
Article: [Current strategies of primary therapy for breast cancer].
[show abstract] [hide abstract]
ABSTRACT: Active clinical researches for breast cancer advance the therapeutic strategies remarkably, however, it seems to be more difficult to choose the appropriate treatment based on the evidence for each patient due to its diversification. Moreover, the striking achievements of various molecular targeting drugs established by basic researches make it complex, since the biological feature of tumor cell must be considered carefully for drug selection. To make it straight, the latest strategies for breast cancer treatment based on both basic and clinical evidences are summarized, especially about surgical and medical treatments of primary therapy for breast cancer.Nippon rinsho. Japanese journal of clinical medicine 06/2010; 68(6):1137-42. -
Article: Reverse genetic analysis of the Caenorhabditis elegans 26S proteasome subunits by RNA interference.
[show abstract] [hide abstract]
ABSTRACT: Reverse genetic analysis was performed on the Caenorhabditis elegans 26S proteasome subunit genes by double-stranded RNA-mediated interference (RNAi). Embryonic and post-embryonic lethality was caused by interference of all of the eight tested 20S core subunits and all of the 19S regulatory particle subunits except for Ce-Rpn9, Ce-Rpn10, and Ce-Rpn12, where RNAi caused no abnormality. However, synthetic suppression of Ce-Rpn10 and Ce-Rpn12 was lethal, whereas neither the combination of Ce-Rpn9 with Ce-Rpn10 nor with Ce-Rpn12 resulted in abnormalities in RNAi. These results indicate that the 26S proteasome is indispensable for embryogenesis and post-embryonic development, although Ce-Rpn9, Ce-Rpn10, and Ce-Rpn12 are not essential, at least under the conditions used. Ce-Rpn10 and Ce-Rpn12 are considered to compensate for the suppression of each other.Biological Chemistry 383(7-8):1263-6. · 2.96 Impact Factor
Top co-authors
Top Journals
Institutions
-
2010–2012
-
Keio University
- Department of Surgery
Tokyo, Tokyo-to, Japan
-
